Instrument Inactif

Communiqués WuXi Biologics (Cayman) Inc. Hong Kong S.E.

Actions

2269

KYG970081090

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

WuXi Biologics Cayman : Named to MSCI ESG Leaders Indexes for Second Consecutive Year	14/06	PU
WuXi Biologics Enhances Manufacturing Capability with the Installation of Three 5,000L Single-Use Bioreactors	06/06	AQ
WuXi facility boosts bioprocessing capacity with new bioreactors	06/06	AQ
WuXi Biologics Cayman : Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment	30/04	PU
WuXi Biologics Selected for S&P Global Sustainability Yearbook 2024	16/04	AQ
WuXi Biologics Wins 2024 CDMO Leadership Awards in All Categories	03/04	AQ
WuXi Biologics Reports Solid 2023 Annual Results	27/03	AQ
WuXi Biologics Named to CDP 'A List' for Water Security	25/03	AQ
WuXi Biologics Cayman : Breaks Ground on CRDMO Center in Singapore	19/03	PU
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment	06/03	AQ
WuXi Biologics Ireland Site Receives Three ISO Certifications	04/03	AQ
WuXi Biologics achieves large-scale manufacturing milestone	31/01	AQ
WuXi Biologics Launches WuXiaADCC PLUSTM for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect	26/01	AQ
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBodyTM	18/01	AQ
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates	12/01	AQ
WUXI BIOLOGICS TO PARTICIAPTE AT 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE	10/01	AQ
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts	09/01	AQ
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating	11/12	AQ
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of 6 g/L/day at Pilot Scale	23/11	AQ
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics	21/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués WuXi Biologics (Cayman) Inc. Hong Kong S.E.

Actions

2269

KYG970081090

Communiqués

Filtres